Please assess the completion status of the following clinical trial:

Trial Title: A Study of IBI362 Evaluating Weight Loss in Obese and Overweight Chinese Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~1. Body mass Index (BMI) ≥28 kilograms per square meter (kg/m²), or ≥24 kg/m² and previous diagnosis with at least one of the following comorbidities: hypertension, dyslipidemia, obstructive sleep apnea~2. History of at least one unsuccessful dietary effort to lose body weight~Exclusion Criteria:~1. Diabetes mellitus~2. Weight change \> 5.0% after diet and exercise control for at least 12 weeks before screening~3. Have used or are currently using weight loss drugs within 3 months before screening~4. History of pancreatitis~5. Family or personal history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN-2)~6. History of moderate to severe depression，or have a history of serious mental illness~7. Any lifetime history of a suicide attempt

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- IBI362 high dose (Type: EXPERIMENTAL): high dose IBI362 administered subcutaneously (SC) once a week.
- IBI362 low dose (Type: EXPERIMENTAL): Low dose IBI362 administered subcutaneously (SC) once a week.
- placebo (Type: PLACEBO_COMPARATOR): placebo administered subcutaneously (SC) once a week.
- IBI362 moderate dose (Type: EXPERIMENTAL): moderate dose IBI362 administered subcutaneously (SC) once a week.
- IBI362 extra high dose (Type: EXPERIMENTAL): extra high dose IBI362 administered subcutaneously (SC) once a week.

Based on this trial design, predict the completion outcome and termination type (if applicable).